These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9618319)

  • 1. Human variability and noncancer risk assessment- An analysis of the default uncertainty factor.
    Renwick AG; Lazarus NR
    Regul Toxicol Pharmacol; 1998 Feb; 27(1 Pt 2):3-20. PubMed ID: 9618319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human variability and noncancer risk assessment--an analysis of the default uncertainty factor.
    Renwick AG; Lazarus NR
    Regul Toxicol Pharmacol; 1998 Feb; 27(1 Pt 1):3-20. PubMed ID: 9629592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2005 Feb; 43(2):203-16. PubMed ID: 15621332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans.
    Dorne JL; Renwick AG
    Toxicol Sci; 2005 Jul; 86(1):20-6. PubMed ID: 15800035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of science-based uncertainty factors in noncancer risk assessment.
    Dourson ML; Felter SP; Robinson D
    Regul Toxicol Pharmacol; 1996 Oct; 24(2 Pt 1):108-20. PubMed ID: 8933624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human variability in hepatic and renal elimination: implications for risk assessment.
    Dorne JL
    J Appl Toxicol; 2007; 27(5):411-20. PubMed ID: 17497760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A procedure for developing risk-based reference doses.
    Gaylor DW; Kodell RL
    Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
    Dorne JL
    Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity and reliability of in vitro systems in safety evaluation.
    Paine AJ
    Environ Toxicol Pharmacol; 1996 Oct; 2(2-3):207-12. PubMed ID: 21781729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of safety or uncertainty factors in the setting of acute reference doses.
    Renwick AG
    Food Addit Contam; 2000 Jul; 17(7):627-35. PubMed ID: 10983588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability and uncertainty in Swedish exposure factors for use in quantitative exposure assessments.
    Filipsson M; Öberg T; Bergbäck B
    Risk Anal; 2011 Jan; 31(1):108-19. PubMed ID: 20723149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of the U.S. Army's health risk assessments for oral exposure to six chemical-warfare agents. Introduction.
    J Toxicol Environ Health A; 2000 Mar; 59(5-6):281-526. PubMed ID: 10742829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
    Kirman CR; Sweeney LM; Corley R; Gargas ML
    Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing human variability in risk assessment--the robustness of the intraspecies uncertainty factor.
    Burin GJ; Saunders DR
    Regul Toxicol Pharmacol; 1999 Dec; 30(3):209-16. PubMed ID: 10620470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation).
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2004 Mar; 42(3):397-421. PubMed ID: 14871582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision of estimates of an ADI (or TDI or PTWI).
    Speijers GJ
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment factors--applications in health risk assessment of chemicals.
    Falk-Filipsson A; Hanberg A; Victorin K; Warholm M; Wallén M
    Environ Res; 2007 May; 104(1):108-27. PubMed ID: 17166493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An adjustment factor for mode-of-action uncertainty with dual-mode carcinogens: the case of naphthalene-induced nasal tumors in rats.
    Bogen KT
    Risk Anal; 2008 Aug; 28(4):1033-51. PubMed ID: 18564993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
    Flynn MA; McNeil DA; Maloff B; Mutasingwa D; Wu M; Ford C; Tough SC
    Obes Rev; 2006 Feb; 7 Suppl 1():7-66. PubMed ID: 16371076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.